Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Sonidegib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 03 Mar 2019 Status changed from active, no longer recruiting to completed.
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.